Last reviewed · How we verify
PECS-1
PECS-1, developed by Memorial Sloan Ketering Cancer Center, is a marketed small molecule with a key composition patent expiring in 2028. The drug's mechanism of interacting with specific biological targets provides a targeted approach to its primary indication. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | PECS-1 |
|---|---|
| Sponsor | Memorial Sloan Kettering Cancer Center |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Pectoral Nerve Block Versus Paravertebral Block In The Incidence of Chronic Pain After Mastectomy: (NA)
- Study of Nerve Block Pain Management in Patients Undergoing a Double Mastectomy With Immediate Reconstruction (PHASE4)
- Effects of Serratus Anterior Plane Block (SAP), Pectoral Nerve Blocks (PECS I-II), and Standard Systemic Analgesia on Early Postoperative Recovery After Coronary Artery Bypass Grafting (NA)
- Phase 2B Upper Extremity Nerve Block Study (PHASE2)
- Dexmedetomidine as an Adjuvant to Bupivacaine in Bilateral PECs for Pain Control After Cardiac Surgeries (PHASE4)
- Ultrasound-Guided PEC I vs SAP Block for Postoperative Analgesia in Modified Radical Mastectomy (NA)
- Pectoral Nerve Block and Serratus Posterior Superior Intercostal Plane Block in Breast Cancer Surgery (NA)
- Comparison of the Analgesic Efficacy of Erector Spinae Plane Block in Breast-Conserving Surgery Versus Serratus Anterior Block Combined With Additional Pecto-Intercostal II Block (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PECS-1 CI brief — competitive landscape report
- PECS-1 updates RSS · CI watch RSS
- Memorial Sloan Kettering Cancer Center portfolio CI